{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T22:32:08Z","timestamp":1775169128492,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,8,8]],"date-time":"2015-08-08T00:00:00Z","timestamp":1438992000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40257-015-0150-8","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T11:14:34Z","timestamp":1438946074000},"page":"447-452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Ivermectin: A Review in Rosacea"],"prefix":"10.1007","volume":"16","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,8]]},"reference":[{"issue":"13","key":"150_CR1","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40265-014-0281-x","volume":"74","author":"FA Moustafa","year":"2014","unstructured":"Moustafa FA, Sandoval LF, Feldman SR. Rosacea: new and emerging treatments. Drugs. 2014;74(13):1457\u201365.","journal-title":"Drugs."},{"key":"150_CR2","doi-asserted-by":"crossref","unstructured":"Wollina U. Recent advances in the understanding and management of rosacea. F1000Prime Rep. 2014;6(50).","DOI":"10.12703\/P6-50"},{"issue":"5","key":"150_CR3","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaad.2014.05.036","volume":"71","author":"F Moustafa","year":"2014","unstructured":"Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014;71(5):973\u201380.","journal-title":"J Am Acad Dermatol."},{"key":"150_CR4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","volume":"25","author":"BE Elewski","year":"2011","unstructured":"Elewski BE, Draelos Z, Dreno B, et al. Rosacea\u2014global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25:188\u2013200.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"14","key":"150_CR5","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1517\/14656566.2014.945423","volume":"15","author":"JQ Rosso Del","year":"2014","unstructured":"Del Rosso JQ. Management of cutaneous rosacea: emphasis on new medical therapies. Expert Opin Pharmacother. 2014;15(14):2029\u201338.","journal-title":"Expert Opin Pharmacother."},{"issue":"1","key":"150_CR6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1468-3083.2011.04310.x","volume":"26","author":"FM Forton","year":"2012","unstructured":"Forton FM. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol. 2012;26(1):19\u201328.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"12","key":"150_CR7","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/exd.12030","volume":"21","author":"C Casas","year":"2012","unstructured":"Casas C, Paul C, Lahfa M, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21(12):906\u201310.","journal-title":"Exp Dermatol."},{"issue":"6","key":"150_CR8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2133.1993.tb00261.x","volume":"128","author":"F Forton","year":"1993","unstructured":"Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol. 1993;128(6):650\u20139.","journal-title":"Br J Dermatol."},{"issue":"1","key":"150_CR9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaad.2004.05.034","volume":"52","author":"F Forton","year":"2005","unstructured":"Forton F, Germaux MA, Brasseur T, et al. Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol. 2005;52(1):74\u201387.","journal-title":"J Am Acad Dermatol."},{"key":"150_CR10","doi-asserted-by":"crossref","unstructured":"Abokwidir M, Fleischer AB. An emerging treatment: topical ivermectin for papulopustular rosacea. J Dermatolog Treat. 2015. doi: 10.3109\/09546634.2014.991672 .","DOI":"10.3109\/09546634.2014.991672"},{"key":"150_CR11","unstructured":"Galderma Laboratories L.P. Soolantra - ivermectin cream: US prescribing information. 2014. http:\/\/www.fda.gov . Accessed 28 July 2015."},{"key":"150_CR12","unstructured":"Galderma Canada Inc. PrRosiver\u2122 (ivermectin) cream, 1\u00a0% w\/w, topical rosacea therapy: Canadian product monograph. 2015. http:\/\/www.hc-sc.gc.ca\/index-eng.php . Accessed 28 July 2015."},{"key":"150_CR13","unstructured":"Galderma (U.K) Ltd. Soolantra 10\u00a0mg\/g cream: UK summary of product characteristics. 2015. http:\/\/www.medicines.org.uk . Accessed 28 July 2015."},{"issue":"11","key":"150_CR14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","volume":"57","author":"X Zhang","year":"2008","unstructured":"Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res. 2008;57(11):524\u20139.","journal-title":"Inflamm Res."},{"issue":"4","key":"150_CR15","first-page":"3","volume":"48","author":"AV Viktorov","year":"2003","unstructured":"Viktorov AV. Ivermectin inhibits activation of Kupffer cells induced by lipopolysaccharide toxin. Antibiot Khimioter. 2003;48(4):3\u20136.","journal-title":"Antibiot Khimioter."},{"issue":"3","key":"150_CR16","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.intimp.2008.12.016","volume":"9","author":"X Zhang","year":"2009","unstructured":"Zhang X, Song Y, Xiong H, et al. Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages. Int Immunopharmacol. 2009;9(3):354\u20139.","journal-title":"Int Immunopharmacol."},{"issue":"6","key":"150_CR17","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1023\/B:BEBM.0000020206.23474.e9","volume":"136","author":"AV Viktorov","year":"2003","unstructured":"Viktorov AV, Yurkiv VA. Effect of ivermectin on function of liver macrophages. Bull Exp Biol Med. 2003;136(6):569\u201371.","journal-title":"Bull Exp Biol Med."},{"issue":"3\u20134","key":"150_CR18","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0165-2427(94)05308-F","volume":"44","author":"M Stankiewicz","year":"1995","unstructured":"Stankiewicz M, Cabaj W, Jonas WE, et al. Influence of ivermectin on cellular and humoral immune responses of lambs. Vet Immunol Immunopathol. 1995;44(3\u20134):347\u201358.","journal-title":"Vet Immunol Immunopathol."},{"issue":"6","key":"150_CR19","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00011-011-0307-8","volume":"60","author":"S Yan","year":"2011","unstructured":"Yan S, Ci X, Chen N, et al. Anti-inflammatory effects of ivermectin in mouse model of allergic asthma. Inflamm Res. 2011;60(6):589\u201396.","journal-title":"Inflamm Res."},{"issue":"12","key":"150_CR20","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-4632.2004.02253.x","volume":"44","author":"AL Dourmishev","year":"2005","unstructured":"Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol. 2005;44(12):981\u20138.","journal-title":"Int J Dermatol."},{"issue":"5 Pt 1","key":"150_CR21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0190-9622(99)70022-8","volume":"41","author":"C Forstinger","year":"1999","unstructured":"Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41(5 Pt 1):775\u20137.","journal-title":"J Am Acad Dermatol."},{"key":"150_CR22","first-page":"88","volume":"127","author":"M Rylojad","year":"2000","unstructured":"Rylojad M, Bourrot E, Eyrand D. Demodecicose profuse au cours d\u2019une leukemie aigue lymphoblastique chez 2 enfants. Efficacite de l\u2019ivermectine. Ann Dermatol Venereol. 2000;127:88.","journal-title":"Ann Dermatol Venereol."},{"issue":"48","key":"150_CR23","doi-asserted-by":"crossref","first-page":"40232","DOI":"10.1074\/jbc.R112.406280","volume":"287","author":"AJ Wolstenholme","year":"2012","unstructured":"Wolstenholme AJ. Glutamate-gated chloride channels. J Biol Chem. 2012;287(48):40232\u20138.","journal-title":"J Biol Chem."},{"key":"150_CR24","unstructured":"Benkali K, Rony F, Graeber M, et al. Clinical pharmacokinetic profile of ivermectin 1\u00a0% cream after dermal applications in subjects with papulopustular rosacea [abstract]. In: American Association of Pharmaceutical Scientists Annual Meeting and Exposition. 2014."},{"issue":"3","key":"150_CR25","first-page":"316","volume":"13","author":"L Stein-Gold","year":"2014","unstructured":"Stein-Gold L, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1\u00a0% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316\u201323.","journal-title":"J Drugs Dermatol."},{"issue":"4","key":"150_CR26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","volume":"172","author":"A Taieb","year":"2015","unstructured":"Taieb A, Ortonne JP, Ruzicka T, et al. Superiority of ivermectin 1\u00a0% cream over metronidazole 0.75\u00a0% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103\u201310.","journal-title":"Br J Dermatol."},{"key":"150_CR27","unstructured":"Data on file, Galderma. 2015."},{"issue":"11","key":"150_CR28","first-page":"1380","volume":"13","author":"L Stein-Gold","year":"2014","unstructured":"Stein-Gold L, Kircik L, Fowler J, et al. Long-term safety of ivermectin 1\u00a0% cream vs azelaic acid 15\u00a0% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13(11):1380\u20136.","journal-title":"J Drugs Dermatol."},{"issue":"3","key":"150_CR29","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/09546630601121078","volume":"18","author":"S Laquieze","year":"2007","unstructured":"Laquieze S, Czernielewski J, Baltas E. Beneficial use of Cetaphil moisturizing cream as part of a daily skin care regimen for individuals with rosacea. J Dermatolog Treat. 2007;18(3):158\u201362.","journal-title":"J Dermatolog Treat."},{"key":"150_CR30","first-page":"71","volume":"93","author":"E Tanghetti","year":"2014","unstructured":"Tanghetti E, Del Rosso JQ, Thiboutot D, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis. 2014;93:71\u20136.","journal-title":"Cutis."},{"key":"150_CR31","first-page":"277","volume":"92","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92:277\u201384.","journal-title":"Cutis."},{"key":"150_CR32","first-page":"18","volume":"93","author":"JQ Rosso Del","year":"2014","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93:18\u201328.","journal-title":"Cutis."},{"issue":"5","key":"150_CR33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jaad.2014.08.027","volume":"72","author":"A Two","year":"2015","unstructured":"Two A, Wu W, Gallo R, et al. Rosacea: part II. Topical and systemic therapies in the treatment of rosacea. J Am Acad Dermatol. 2015;72(5):761\u201370.","journal-title":"J Am Acad Dermatol."}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-015-0150-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-015-0150-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-015-0150-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:28:35Z","timestamp":1559503715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-015-0150-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,8]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s40257-015-0150-8","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,8]]}}}